D-2-Hydroxyglutarate in Glioma Biology

Isocitrate dehydrogenase (IDH) mutations are common genetic abnormalities in glioma, which result in the accumulation of an “oncometabolite”, D-2-hydroxyglutarate (D-2-HG). Abnormally elevated D-2-HG levels result in a distinctive pattern in cancer biology, through competitively inhibiting α-ketoglu...

Descripción completa

Detalles Bibliográficos
Autores principales: Chou, Fu-Ju, Liu, Yang, Lang, Fengchao, Yang, Chunzhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464856/
https://www.ncbi.nlm.nih.gov/pubmed/34571995
http://dx.doi.org/10.3390/cells10092345
_version_ 1784572721529618432
author Chou, Fu-Ju
Liu, Yang
Lang, Fengchao
Yang, Chunzhang
author_facet Chou, Fu-Ju
Liu, Yang
Lang, Fengchao
Yang, Chunzhang
author_sort Chou, Fu-Ju
collection PubMed
description Isocitrate dehydrogenase (IDH) mutations are common genetic abnormalities in glioma, which result in the accumulation of an “oncometabolite”, D-2-hydroxyglutarate (D-2-HG). Abnormally elevated D-2-HG levels result in a distinctive pattern in cancer biology, through competitively inhibiting α-ketoglutarate (α-KG)/Fe(II)-dependent dioxgenases (α-KGDDs). Recent studies have revealed that D-2-HG affects DNA/histone methylation, hypoxia signaling, DNA repair, and redox homeostasis, which impacts the oncogenesis of IDH-mutated cancers. In this review, we will discuss the current understanding of D-2-HG in cancer biology, as well as the emerging opportunities in therapeutics in IDH-mutated glioma.
format Online
Article
Text
id pubmed-8464856
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84648562021-09-27 D-2-Hydroxyglutarate in Glioma Biology Chou, Fu-Ju Liu, Yang Lang, Fengchao Yang, Chunzhang Cells Review Isocitrate dehydrogenase (IDH) mutations are common genetic abnormalities in glioma, which result in the accumulation of an “oncometabolite”, D-2-hydroxyglutarate (D-2-HG). Abnormally elevated D-2-HG levels result in a distinctive pattern in cancer biology, through competitively inhibiting α-ketoglutarate (α-KG)/Fe(II)-dependent dioxgenases (α-KGDDs). Recent studies have revealed that D-2-HG affects DNA/histone methylation, hypoxia signaling, DNA repair, and redox homeostasis, which impacts the oncogenesis of IDH-mutated cancers. In this review, we will discuss the current understanding of D-2-HG in cancer biology, as well as the emerging opportunities in therapeutics in IDH-mutated glioma. MDPI 2021-09-07 /pmc/articles/PMC8464856/ /pubmed/34571995 http://dx.doi.org/10.3390/cells10092345 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chou, Fu-Ju
Liu, Yang
Lang, Fengchao
Yang, Chunzhang
D-2-Hydroxyglutarate in Glioma Biology
title D-2-Hydroxyglutarate in Glioma Biology
title_full D-2-Hydroxyglutarate in Glioma Biology
title_fullStr D-2-Hydroxyglutarate in Glioma Biology
title_full_unstemmed D-2-Hydroxyglutarate in Glioma Biology
title_short D-2-Hydroxyglutarate in Glioma Biology
title_sort d-2-hydroxyglutarate in glioma biology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464856/
https://www.ncbi.nlm.nih.gov/pubmed/34571995
http://dx.doi.org/10.3390/cells10092345
work_keys_str_mv AT choufuju d2hydroxyglutarateingliomabiology
AT liuyang d2hydroxyglutarateingliomabiology
AT langfengchao d2hydroxyglutarateingliomabiology
AT yangchunzhang d2hydroxyglutarateingliomabiology

Ejemplares similares